

Ref: MHL/Sec&Legal/2024-25/64

Date: November 08, 2024

To,
BSE Limited **National Stock Exchange of India Ltd.**
Scrip Code: 542650 Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Press Release

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith is the Press Release as mentioned below:

"Metropolis Healthcare reports 31.0% YoY Profit after Tax (PAT) Growth in Q2 FY2024-25"

You are requested to take the above information on record.


Thanking you,
Yours faithfully,

For **Metropolis Healthcare Limited**

Kamlesh C Kulkarni
Head – Legal & Secretarial

Encl: A/a



PRESS RELEASE**Metropolis Healthcare reports 31.0% YoY Profit after Tax (PAT)
Growth in Q2 FY2024-25**

Mumbai, November 8th, 2024: Metropolis Healthcare Limited (NSE: METROPOLIS | BSE: 542650), one of India's leading and reputed diagnostic chains, known for its commitment to quality and scientific excellence, today announced its unaudited consolidated financial results for the quarter ended September 30th, 2024.

Q2 FY25 Key Financial Highlights

- **Revenue from Operations** stood at INR 350 crores, a growth of 13.4% Y-o-Y basis, well within guidance.
- **Consistent Performance driven by sustained growth in Patient Volumes and Test Volumes**, which stood at 7% and 8%, respectively for the quarter. Increase in Revenue Per Patient by 6%.
- **Reported EBITDA** stood at INR 92 crores, with a growth of 22.2% Y-o-Y.
- **Profit after Tax (PAT)** stood at INR 47 crores with a growth of 31.0% Y-o-Y, margins at 13.4%, up from 11.6% for Q2FY24, up by 180 bps Y-o-Y.

“We are delighted to share that Q2 FY25 has been a successful quarter, marked by a significant increase in revenue, driven by strong profit after tax (PAT) growth and solid execution from our management team. As we move forward, we will remain focused on advancing our testing capabilities to maintain our differentiated position in the market and to support sustainable long-term growth. Our consistent performance reflects our ability to increase patient volumes while maintaining robust growth trajectories in both B2C and B2B segments. With a solid pipeline of future initiatives, including potential mergers and acquisitions, we see a long growth runway ahead in a normalized competitive landscape and are well-positioned to capitalize on these opportunities, ensuring long-term value creation for our shareholders.”

~ **Ameera Shah, Executive Chairperson & Whole-time Director, Metropolis Healthcare Limited.**

“We have consistently achieved substantial growth, with revenue increasing by 13.4% and EBITDA rising by 22.2% year-on-year. This strong performance has been fuelled by a 21% YoY growth in B2C revenue, along with expansion in Tier 3 cities and an improvement in our average revenue per patient. Key growth areas, including our Specialty and TruHealth segments, have also contributed significantly. As we continue to broaden our footprint through our extensive network and valued partnerships, this strategic approach

strengthens our position in a competitive landscape and paves the way for sustainable, long-term growth.”
 ~ **Surendran Chemmenkotil, Chief Executive Officer, Metropolis Healthcare Limited.**

In INR Crs.	Q2FY25	Q2FY24	Y-o-Y (%)
Revenue from Operations	349.8	308.5	13.4%
Reported EBITDA	91.5	74.9	22.2%
Reported EBITDA Margins (%)	26.2%	24.3%	190 bps
Profit After Tax	46.7	35.7	31.0%
PAT Margin (%)	13.4%	11.6%	180 bps

About Metropolis: Established in 1981, Metropolis Healthcare Limited is the leading diagnostics company in India, with a widespread presence in 22 states, 3 Union Territories and over 700 towns. Metropolis touches millions of lives each year by providing actionable health insights to patients and doctors. Metropolis offers a comprehensive range of more than 4,000 plus tests and profiles, including advanced tests for the diagnosis of cancer, neurological disorders, infectious diseases, and various genetic abnormalities. The company is empowered with a robust network of 202 labs, 4,336 service centers and over 10,000 touch points. Metropolis’ commitment to quality and accuracy in each test is reinforced by its consistent CAP proficiency score of more than 98% over the past decade, placing it among the top 1% laboratories worldwide for quality assurance. The Metropolis philosophy rests on the pillars of technological superiority, a warm, patient centric approach and reliable diagnostic reports. For more information, please visit www.metropolisindia.com or click on [Twitter](#), [Facebook](#), or [LinkedIn](#)

Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Company: Metropolis Healthcare Ltd.

CIN -L73100MH2000PLC192798

Mr. Jeyasingh Balakrishnan – Head - Corporate Communications

jeyasingh.b@metropolisindia.com

www.metropolisindia.com

Investor Relations Advisors: Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Mr. Shogun Jain / Mr. Sagar Shroff

+91 77383 77756 / +91 98205 19303

shogun.jain@sgapl.net / sagar.shroff@sgapl.net